Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group

Carly J. Callender, Marcelo Fernandez-Vina, Mary S. Leffell, Andrea A. Zachary

Research output: Contribution to journalArticle

Abstract

Clinical studies have demonstrated that HLA-DP-specific antibodies can be detrimental to a transplanted kidney. The number of patients affected is proportional to the frequency of DP antibodies. We determined the frequency of HLA-DP-specific antibodies en toto and in the absence of cross-reactive DR antibodies. Of 650 waitlisted renal patients, 271 (42%) were reactive with HLA-DP antigens in solid-phase immunoassays. Of these 271 sera, 58 (21%) were negative for reactivity with cross-reactive DR antigens, and 16 (5.9%) had no class II antibody other than DP. Eliminating sera containing DR cross-reactive antibodies reduced the frequency but not the overall strength of DP antibodies. Although most DP antibodies were not expected to yield a positive cytotoxicity crossmatch, 2 DP-specific antibodies yielded cytotoxic crossmatch tests with titers of >512. The occurrence of HLA-DP-specific antibody differed significantly between previously transplanted (62%) and nontransplanted (38%) patients, but no difference was observed among patients categorized by race or sex. One serum demonstrated strong cross-reactivity between DP and DRB1*01:03 in the absence of DR1 or DR11 reactivity. Sequence alignments were performed and a possible new cross-reactivity between DRB1*01:03 and DP2, DP9, DP10, DP13, DP16, and DP17 was defined. Two additional sera confirmed this cross-reactivity.

Original languageEnglish (US)
Pages (from-to)175-179
Number of pages5
JournalHuman Immunology
Volume73
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

HLA-DP Antigens
Antibodies
Serum
Kidney
Immunoglobulin Isotypes
Sequence Alignment
Immunoassay

Keywords

  • CREG
  • DP
  • HLA-DP

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Callender, C. J., Fernandez-Vina, M., Leffell, M. S., & Zachary, A. A. (2012). Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group. Human Immunology, 73(2), 175-179. https://doi.org/10.1016/j.humimm.2011.11.006

Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group. / Callender, Carly J.; Fernandez-Vina, Marcelo; Leffell, Mary S.; Zachary, Andrea A.

In: Human Immunology, Vol. 73, No. 2, 02.2012, p. 175-179.

Research output: Contribution to journalArticle

Callender, CJ, Fernandez-Vina, M, Leffell, MS & Zachary, AA 2012, 'Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group', Human Immunology, vol. 73, no. 2, pp. 175-179. https://doi.org/10.1016/j.humimm.2011.11.006
Callender, Carly J. ; Fernandez-Vina, Marcelo ; Leffell, Mary S. ; Zachary, Andrea A. / Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group. In: Human Immunology. 2012 ; Vol. 73, No. 2. pp. 175-179.
@article{40bd0b4edfb14ed4a976b8d1a508c9d2,
title = "Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group",
abstract = "Clinical studies have demonstrated that HLA-DP-specific antibodies can be detrimental to a transplanted kidney. The number of patients affected is proportional to the frequency of DP antibodies. We determined the frequency of HLA-DP-specific antibodies en toto and in the absence of cross-reactive DR antibodies. Of 650 waitlisted renal patients, 271 (42{\%}) were reactive with HLA-DP antigens in solid-phase immunoassays. Of these 271 sera, 58 (21{\%}) were negative for reactivity with cross-reactive DR antigens, and 16 (5.9{\%}) had no class II antibody other than DP. Eliminating sera containing DR cross-reactive antibodies reduced the frequency but not the overall strength of DP antibodies. Although most DP antibodies were not expected to yield a positive cytotoxicity crossmatch, 2 DP-specific antibodies yielded cytotoxic crossmatch tests with titers of >512. The occurrence of HLA-DP-specific antibody differed significantly between previously transplanted (62{\%}) and nontransplanted (38{\%}) patients, but no difference was observed among patients categorized by race or sex. One serum demonstrated strong cross-reactivity between DP and DRB1*01:03 in the absence of DR1 or DR11 reactivity. Sequence alignments were performed and a possible new cross-reactivity between DRB1*01:03 and DP2, DP9, DP10, DP13, DP16, and DP17 was defined. Two additional sera confirmed this cross-reactivity.",
keywords = "CREG, DP, HLA-DP",
author = "Callender, {Carly J.} and Marcelo Fernandez-Vina and Leffell, {Mary S.} and Zachary, {Andrea A.}",
year = "2012",
month = "2",
doi = "10.1016/j.humimm.2011.11.006",
language = "English (US)",
volume = "73",
pages = "175--179",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group

AU - Callender, Carly J.

AU - Fernandez-Vina, Marcelo

AU - Leffell, Mary S.

AU - Zachary, Andrea A.

PY - 2012/2

Y1 - 2012/2

N2 - Clinical studies have demonstrated that HLA-DP-specific antibodies can be detrimental to a transplanted kidney. The number of patients affected is proportional to the frequency of DP antibodies. We determined the frequency of HLA-DP-specific antibodies en toto and in the absence of cross-reactive DR antibodies. Of 650 waitlisted renal patients, 271 (42%) were reactive with HLA-DP antigens in solid-phase immunoassays. Of these 271 sera, 58 (21%) were negative for reactivity with cross-reactive DR antigens, and 16 (5.9%) had no class II antibody other than DP. Eliminating sera containing DR cross-reactive antibodies reduced the frequency but not the overall strength of DP antibodies. Although most DP antibodies were not expected to yield a positive cytotoxicity crossmatch, 2 DP-specific antibodies yielded cytotoxic crossmatch tests with titers of >512. The occurrence of HLA-DP-specific antibody differed significantly between previously transplanted (62%) and nontransplanted (38%) patients, but no difference was observed among patients categorized by race or sex. One serum demonstrated strong cross-reactivity between DP and DRB1*01:03 in the absence of DR1 or DR11 reactivity. Sequence alignments were performed and a possible new cross-reactivity between DRB1*01:03 and DP2, DP9, DP10, DP13, DP16, and DP17 was defined. Two additional sera confirmed this cross-reactivity.

AB - Clinical studies have demonstrated that HLA-DP-specific antibodies can be detrimental to a transplanted kidney. The number of patients affected is proportional to the frequency of DP antibodies. We determined the frequency of HLA-DP-specific antibodies en toto and in the absence of cross-reactive DR antibodies. Of 650 waitlisted renal patients, 271 (42%) were reactive with HLA-DP antigens in solid-phase immunoassays. Of these 271 sera, 58 (21%) were negative for reactivity with cross-reactive DR antigens, and 16 (5.9%) had no class II antibody other than DP. Eliminating sera containing DR cross-reactive antibodies reduced the frequency but not the overall strength of DP antibodies. Although most DP antibodies were not expected to yield a positive cytotoxicity crossmatch, 2 DP-specific antibodies yielded cytotoxic crossmatch tests with titers of >512. The occurrence of HLA-DP-specific antibody differed significantly between previously transplanted (62%) and nontransplanted (38%) patients, but no difference was observed among patients categorized by race or sex. One serum demonstrated strong cross-reactivity between DP and DRB1*01:03 in the absence of DR1 or DR11 reactivity. Sequence alignments were performed and a possible new cross-reactivity between DRB1*01:03 and DP2, DP9, DP10, DP13, DP16, and DP17 was defined. Two additional sera confirmed this cross-reactivity.

KW - CREG

KW - DP

KW - HLA-DP

UR - http://www.scopus.com/inward/record.url?scp=84856334125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856334125&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2011.11.006

DO - 10.1016/j.humimm.2011.11.006

M3 - Article

C2 - 22138757

AN - SCOPUS:84856334125

VL - 73

SP - 175

EP - 179

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 2

ER -